King Edward Memorial Hospital Obstetrics & Gynaecology

ADULT

NALOXONE

This document should be read in conjunction with this **DISCLAIMER**

Presentation	Ampoule: 400microgram/mL						
	Combination Products:						
	Oxycodone/Naloxone Modified Release Tablets (Targin®):						
	2.5/1.25mg, 5/2.5mg, 10/5mg, 20/10mg, 40/20mg						
	Buprenorphine/Naloxone sublingual films (Suboxone®):						
	2mg/500microg, 8mg/2mg						
Dose	Reversal of opioid toxicity						
	Refer to Adult Resuscitation Drug Protocol - Naloxone and Epidural Complications and Post-Operative Pain						
	Relief of intrathecal opioid induced itch						
	Intravenous:						
	50 – 150 microgram, hourly when necessary.						
	CPOP						
	Sublingual:						
	Refer to Community Programme for Opioid Pharmacotherapy patients in the hospital setting						
Administration	Refer to KEMH Clinical Guidelines (links below)						
	IV injection: Preferred route						
	Option A						
	Administration: Inject undiluted at 2 to 3 minute intervals.						
	Option B (for small doses)						
	Dilution: Dilute 400microg (one ampoule) to 8mL with Water for Injections of Sodium Chloride 0.9%. Concentration is 50microg/mL						
	Administration: Inject as directed						

	IV infusion.					
	IV infusion: Dilution: Dilute 2 mg (5 amoules) in 500 ml of Sedium Chloride 0.0% or					
	Dilution: Dilute 2 mg (5 ampoules) in 500 mL of Sodium Chloride 0.9% or Glucose 5%. Concentration is 4 microgram/mL					
	Administration: Give as a continuous infusion.					
	IM injection:					
	Suitable if the IV route is not available. Inject into the upper arm or thigh. In an emergency, the injection can be given through clothing. Repeat the dose after 3 to 5 minutes if the person is still not breathing.					
	SUBCUT injection:					
	Suitable if the IV route is not available.					
Drognonous	There are limited published reports describing the use of polygons in					
Pregnancy	There are limited published reports describing the use of naloxone in pregnancy, other than during labour. If acute opioid toxicity is evident in the pregnant woman, naloxone therapy should not be withheld, but monitoring of infant respiratory and heart rate is recommended.					
	Contact the Obstetrics Medicines Information Service for more information.					
Breastfeeding	Considered safe to use - monitor breastfed infants of opioid-dependent women for signs of withdrawal.					
	Contact the Obstetrics Medicines Information Service for more information.					
Monitoring	Sudden or complete reversal of opioid overdose may cause agitated delirium in opioid-dependent patients and myocardial infarction in elderly patients or those with coronary artery disease. To avoid acute withdrawal titrate doses of 50–200 microgram every 2 to 3 minutes.					
	Naloxone has a short duration of action (half-life in adults is approximately 1 hour). A continuous infusion may be required to reverse the effect of a long-acting opioid such as methadone or sustained-release forms of morphine or oxycodone. Monitor level of sedation and respiratory function					
Clinical Guidelines and	Adult Resuscitation Drug Protocol - Naloxone					
	Epidural Complications					
Policies	Epidural and Spinal- Side Effects					
	Post-Operative Pain					
	Intrathecal Morphine					
	Intramuscular Morphine					
	Pethidine Intramuscular Administration in Labour					
	Intravenous Patient-Controlled Analgesia in Labour					
	Recognising and Responding to Clinical Deterioration					
	Palliative Care					
1	<u> </u>					

References	The Royal Women's Hospital. Naloxone. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2017 [cited 2017 Sep 27]. Available from: https://thewomenspbmg.org.au/
	Australian Medicines Handbook. Naloxone. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2017 [cited 2017 Sep 27]. Available from: https://amhonline.amh.net.au/
	Society of Hospital Pharmacists of Australia. Naloxone. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2017 [cited 2017 April 27]. Available from: http://aidh.hcn.com.au

Keywords:	Naloxone, opioid antidote, overdose, intoxication, itch, sedation, opioid reversal					
Publishing:						
Document owner:	Chief Pharmacist					
Author / Reviewer:	KEMH Pharmacy Department					
Date first issued:	Oct 2015		Version:	3.0		
Last reviewed:	Sept 2017		Next review date:	Sept 2020		
Endorsed by:	Medicines and Therapeutics Committee		Date:	Jan 2018		
Standards Applicable:	NSQHS Standards: 1 Clinical Care is Guided by Current Best Practice 4 Medication Safety					
Printed or personally saved electronic copies of this document are considered uncontrolled						

© Department of Health Western Australia 2017

Access the current version from the WNHS website.